GlassScriptPhysician profile
Ratna Acharya
NPI 1235740945
$1,170.98
in general payments reported to CMS, 2019-2025
17 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.49 · 2022: $186 · 2023: $343 · 2024: $277 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.71 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $165.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $134.99 | 2022-2024 | Trelegy Ellipta |
| Abbvie INC. | $114.91 | 2022-2025 | Ubrelvy |
| Novo Nordisk INC | $111.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Cranial Technologies, INC | $72.90 | 2022-2024 | Doc Band |
| Organon LLC | $60.27 | 2021-2022 | |
| Alk-Abello, INC | $55.87 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Dexcom, INC. | $55.18 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $54.50 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $44.60 | 2023 | |
| Lilly USA, LLC | $21.02 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $19.85 | 2023 | Vaxneuvance, Proquad, Vaxelis |
| Amgen INC. | $19.75 | 2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $18.92 | 2023 | Nuzyra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.39 | 2024 | Caplyta |
| Cipher Pharmaceuticals US LLC | $15.81 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratna Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.